ASH 2023 preview – the first cell therapy winners
Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.
Schrödinger jumps on the PRMT5 bandwagon
Meanwhile, Bristol Myers Squibb hands back two mystery projects.
Cellectis gets another bailout
Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.
Multi-specific antibodies and cell therapies enter phase 1
Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.
